Published in Oncology (Williston Park) on January 01, 2010
Treating ALK-positive lung cancer--early successes and future challenges. Nat Rev Clin Oncol (2012) 1.97
Genetic and biochemical alterations in non-small cell lung cancer. Biochem Res Int (2012) 1.05
Genomic impact of cigarette smoke, with application to three smoking-related diseases. Crit Rev Toxicol (2012) 1.00
Variants in inflammation genes are implicated in risk of lung cancer in never smokers exposed to second-hand smoke. Cancer Discov (2011) 0.92
Hormonal Replacement Therapy and the Risk of Lung Cancer in Women: An Adaptive Meta-analysis of Cohort Studies. J Prev Med Public Health (2015) 0.86
Timeliness of Diagnosing Lung Cancer: Number of Procedures and Time Needed to Establish Diagnosis: Being Right the First Time. Medicine (Baltimore) (2015) 0.86
Human papillomavirus infection and risk of lung cancer in never-smokers and women: an 'adaptive' meta-analysis. Epidemiol Health (2015) 0.82
Non-small cell lung cancer in never smokers: a clinical entity to be identified. Clinics (Sao Paulo) (2011) 0.82
Lung cancer in never smokers. Semin Respir Crit Care Med (2011) 0.81
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors. J Vis Exp (2016) 0.79
Prevalence of and risk factors for postoperative pulmonary complications after lung cancer surgery in patients with early-stage COPD. Int J Chron Obstruct Pulmon Dis (2016) 0.78
Lung cancer in 'never-smokers': beyond EGFR mutations and EGFR-TK inhibitors. Oncology (Williston Park) (2010) 0.78
RARβ2 hypermethylation is associated with poor recurrence-free survival in never-smokers with adenocarcinoma of the lung. Clin Epigenetics (2015) 0.78
At the crossroads: EGFR and PTHrP signaling in cancer-mediated diseases of bone. Odontology (2012) 0.78
Modifiable risk factors of lung cancer in "never-smoker" women. Epidemiol Health (2015) 0.77
Lung cancer in 'Never-smokers': molecular factors trump risk factors. Oncology (Williston Park) (2010) 0.76
Evaluation of pulmonary nodules in Asian population. J Thorac Dis (2016) 0.75
Fire without smoke: lung cancer in 'never-smokers'. Oncology (Williston Park) (2010) 0.75
Lung cancer in never smokers: a review. J Clin Oncol (2007) 5.49
Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol (2013) 5.21
INTERESTing biomarker to select IDEAL patients for epidermal growth factor receptor tyrosine kinase inhibitors: yes, for EGFR mutation analysis, others, I PASS. J Clin Oncol (2009) 4.53
Non-small cell lung cancer. J Natl Compr Canc Netw (2010) 3.93
A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med (2006) 3.37
Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol (2008) 2.71
Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol (2008) 2.59
Non-small cell lung cancer, version 2.2013. J Natl Compr Canc Netw (2013) 2.56
Non-small cell lung cancer. J Natl Compr Canc Netw (2012) 2.40
DGIdb: mining the druggable genome. Nat Methods (2013) 2.26
In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging (2003) 2.25
Clinical applications of The Cancer Genome Atlas project (TCGA) for squamous cell lung carcinoma. Oncology (Williston Park) (2013) 2.16
Biostatistics primer: what a clinician ought to know: hazard ratios. J Thorac Oncol (2011) 2.15
Small cell lung cancer. J Natl Compr Canc Netw (2013) 2.04
Time to activate lung cancer clinical trials and patient enrollment: a representative comparison study between two academic centers across the atlantic. J Clin Oncol (2010) 2.00
Differential prognostic impact of comorbidity. J Clin Oncol (2004) 1.92
EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity. Cancer Res (2007) 1.91
Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study. J Clin Oncol (2009) 1.90
Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol (2006) 1.84
Clinical next-generation sequencing in patients with non-small cell lung cancer. Cancer (2014) 1.76
Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancer. Lung Cancer (2005) 1.76
Non-small cell lung cancer, version 1.2015. J Natl Compr Canc Netw (2014) 1.71
Review of ongoing clinical trials in non-small cell lung cancer: a status report for 2009 from the ClinicalTrials.gov website. J Thorac Oncol (2010) 1.65
A phase I/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages I to III non-small-cell lung cancer: phase I results of RTOG 0117. Int J Radiat Oncol Biol Phys (2010) 1.64
Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey. J Thorac Oncol (2010) 1.58
Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol (2006) 1.56
Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial. J Clin Oncol (2012) 1.55
Presentation and stage-specific outcomes of lifelong never-smokers with non-small cell lung cancer (NSCLC). J Thorac Oncol (2007) 1.55
Influenza vaccination in patients with cancer: an overview. Oncology (Williston Park) (2010) 1.44
Esophageal carcinoma with celiac nodal metastases; curative or palliative? J Thorac Oncol (2008) 1.44
Response to bortezomib (velcade) in a case of advanced bronchiolo-alveolar carcinoma (BAC). A case report. Lung Cancer (2006) 1.40
MicroRNA profiling and prediction of recurrence/relapse-free survival in stage I lung cancer. Carcinogenesis (2012) 1.40
The effect of FDG-PET on the stage distribution of non-small cell lung cancer. J Thorac Oncol (2008) 1.38
Distinctive characteristics of non-small cell lung cancer (NSCLC) in the young: a surveillance, epidemiology, and end results (SEER) analysis. J Thorac Oncol (2010) 1.33
A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing. Clin Cancer Res (2007) 1.32
The epidemiology of bronchioloalveolar carcinoma over the past two decades: analysis of the SEER database. Lung Cancer (2004) 1.32
A survey of Internet utilization among patients with cancer. Support Care Cancer (2010) 1.32
Definitive chemoradiation for the treatment of locally advanced non small-cell lung cancer. J Clin Oncol (2007) 1.31
Molecular genetics of lung cancer in people who have never smoked. Lancet Oncol (2008) 1.28
Prognostic significance of tumor size in patients with stage III non-small-cell lung cancer: a surveillance, epidemiology, and end results (SEER) survey from 1998 to 2003. J Thorac Oncol (2012) 1.27
Smoking relapse during the first year after treatment for early-stage non-small-cell lung cancer. Cancer Epidemiol Biomarkers Prev (2006) 1.26
Transcriptome sequencing reveals altered long intergenic non-coding RNAs in lung cancer. Genome Biol (2014) 1.25
A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer. J Thorac Oncol (2011) 1.24
Improving survival for stage IV non-small cell lung cancer: a surveillance, epidemiology, and end results survey from 1990 to 2005. J Thorac Oncol (2009) 1.24
Use of microRNA expression levels to predict outcomes in resected stage I non-small cell lung cancer. J Thorac Oncol (2010) 1.22
Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. J Clin Oncol (2004) 1.21
Tracheo-esophageal fistula with bevacizumab after mediastinal radiation. J Thorac Oncol (2008) 1.19
Metastatic cancer involving bladder: a review. Can J Urol (2007) 1.16
Prognostic value of preoperative positron emission tomography in resected stage I non-small cell lung cancer. J Thorac Oncol (2008) 1.12
Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B. Cancer (2005) 1.09
Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer. J Thorac Oncol (2012) 1.08
Small cell lung cancer. J Natl Compr Canc Netw (2011) 1.07
Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097). J Thorac Oncol (2010) 1.07
Risk of recurrence of resected stage I non-small cell lung cancer in elderly patients as compared with younger patients. J Thorac Oncol (2009) 1.06
Thymomas and thymic carcinomas: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2013) 1.06
Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer. Oncologist (2010) 1.04
Hedgehog signaling pathway and lung cancer. J Thorac Oncol (2007) 1.04
An eHealth system supporting palliative care for patients with non-small cell lung cancer: a randomized trial. Cancer (2013) 1.02
Smoking urges and relapse among lung cancer patients: findings from a preliminary retrospective study. Prev Med (2004) 1.02
An emerging place for lung cancer genomics in 2013. J Thorac Dis (2013) 1.02
Malignant pleural mesothelioma. J Natl Compr Canc Netw (2012) 1.01
Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2017) 0.99
A phase II study of topotecan and docetaxel in patients with sensitive relapse small cell lung cancer. Acta Oncol (2008) 0.99
Identification of a novel tumor suppressor gene p34 on human chromosome 6q25.1. Cancer Res (2007) 0.98
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol (2015) 0.97
Barriers to enrollment in non-small cell lung cancer therapeutic clinical trials. J Thorac Oncol (2011) 0.96
Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer: a safety, feasibility, and efficacy study from the Hoosier Oncology Group. J Thorac Oncol (2010) 0.95
Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response. Clin Cancer Res (2003) 0.94
EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer. J Thorac Oncol (2008) 0.92
A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report. J Thorac Oncol (2006) 0.91
Clinical-pathologic conference in general thoracic surgery: Cardiac lymphoma. J Thorac Cardiovasc Surg (2005) 0.91
Rapid induction of lung adenocarcinoma by fibroblast growth factor 9 signaling through FGF receptor 3. Cancer Res (2013) 0.91
Assessing quality of life following neoadjuvant therapy for early stage non-small cell lung cancer (NSCLC): results from a prospective analysis using the Lung Cancer Symptom Scale (LCSS). Support Care Cancer (2008) 0.90
Biostatistics primer: what a clinician ought to know--prognostic and predictive factors. J Thorac Oncol (2013) 0.89
Novel agents in the treatment of lung cancer: conference summary statement. Clin Cancer Res (2004) 0.88
Pemetrexed in second line and beyond small cell lung cancer: a Hoosier Oncology Group phase II study. J Thorac Oncol (2009) 0.88
A clinical model to estimate recurrence risk in resected stage I non-small cell lung cancer. Am J Clin Oncol (2008) 0.85
Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer. J Thorac Oncol (2013) 0.85
Genomics of squamous cell lung cancer. Oncologist (2013) 0.85
Annual review of advances in lung cancer clinical research: a report for the year 2009. J Thorac Oncol (2010) 0.85
Prognostic value of fluorodeoxyglucose positron emission tomography in non-small cell lung cancer: a review. J Thorac Oncol (2006) 0.84
One more fallen star--ZODIAC and its implications. Lancet Oncol (2010) 0.84
Pneumocystis pneumonia in a patient with non-small cell lung cancer (NSCLC) treated with pemetrexed containing regimen. Lung Cancer (2007) 0.84
Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignancies. Cancer Chemother Pharmacol (2008) 0.84
Phase 2 study of pemetrexed plus carboplatin, or pemetrexed plus cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/B non-small-cell lung cancer. J Thorac Oncol (2013) 0.84
Novel agents in the treatment of lung cancer: Fourth Cambridge Conference. Clin Cancer Res (2007) 0.83
A phase I trial of sunitinib and rapamycin in patients with advanced non-small cell lung cancer. Chemotherapy (2013) 0.82
Lung cancer in never smokers: a new hot area of research. Lancet Oncol (2010) 0.82
Radiation-induced myonecrosis presenting as a subcutaneous mass after combined modality therapy for non-small cell lung cancer. J Thorac Oncol (2007) 0.82
Stabilization of disease after targeted therapy in a thymic carcinoma with KIT mutation detected by clinical next-generation sequencing. J Thorac Oncol (2014) 0.81
Vaccines and immunotherapy for non-small cell lung cancer. J Thorac Oncol (2010) 0.81
Recent advances in lung cancer: summary of presentations from the 45th annual meeting of the American Society of Clinical Oncology (2009). J Thorac Oncol (2009) 0.81
A phase I study of bexarotene and rosiglitazone in patients with refractory cancers. Chemotherapy (2008) 0.81
Insulin-like growth factor and lung cancer. J Thorac Oncol (2006) 0.81
Non-small cell lung cancer. J Natl Compr Canc Netw (2008) 0.81